Molecular biomarkers predictive of sertraline treatment response in young children with fragile X syndrome

Brain and Development

Volumn 39, Issue 6, 2017, Pages 483-492

  AlOlaby, Reem Rafik ^a   Sweha, Stefan R ^a   Silva, Marisol ^a   Durbin Johnson, Blythe ^a   Yrigollen, Carolyn M ^a   Pretto, Dalyir ^a   Hagerman, Randi J ^a,b   Tassone, Flora ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

BDNF; Cytochrome P450; Fragile X syndrome; Molecular biomarkers; Neurotransmitters; Selective serotonin reuptake inhibitor; Serotonin; Sertraline

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; BRAIN DERIVED NEUROTROPHIC FACTOR; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; GELATINASE B; SEROTONIN TRANSPORTER; SERTRALINE; AMINE OXIDASE (FLAVIN CONTAINING); BIOLOGICAL MARKER; CYTOCHROME P450; MONOAMINE OXIDASE A, HUMAN; SEROTONIN UPTAKE INHIBITOR; SLC6A4 PROTEIN, HUMAN;

ARTICLE; CHILD; CLINICAL ASSESSMENT; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; FEMALE; FOLLOW UP; FRAGILE X SYNDROME; GENETIC ASSOCIATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRESCHOOL LANGUAGE SCALE; PROCEDURES; SOCIAL PARTICIPATION; TREATMENT RESPONSE; VISUAL ANALOG SCALE; AUTISM; BLOOD; COHORT ANALYSIS; DOUBLE BLIND PROCEDURE; GENETICS; METABOLISM; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; SEVERITY OF ILLNESS INDEX;

AUTISM SPECTRUM DISORDER; BIOMARKERS; BRAIN-DERIVED NEUROTROPHIC FACTOR; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; DOUBLE-BLIND METHOD; FEMALE; FRAGILE X SYNDROME; GENOTYPE; HUMANS; MALE; MATRIX METALLOPROTEINASE 9; MONOAMINE OXIDASE; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS; SERTRALINE; SEVERITY OF ILLNESS INDEX;

EID: 85013779755     PISSN: 03877604     EISSN: 18727131     Source Type: Journal    
DOI: 10.1016/j.braindev.2017.01.012     Document Type: Article

References (44)

1. [1] Harris, S.W., Hessl, D., Goodlin-Jones, B., Ferranti, J., Bacalman, S., Barbato, I., et al. Autism profiles of males with fragile X syndrome. Am J Ment Retard 113 (2008), 427–438.
2. [2] Hagerman, R.J., Hagerman, P.J., Fragile X Syndrome: diagnosis, treatment, and research. 2002, The Johns Hopkins University Press, Baltimore, 3–109.
3. [3] Contractor, A., Klyachko, V.A., Portera-Cailliau, C., Altered neuronal and circuit excitability in fragile X syndrome. Neuron 87 (2015), 699–715.
4. [4] Chugani, D.C., Muzik, O., Behen, M., Rothermel, R., Janisse, J.J., Lee, J., et al. Developmental changes in brain serotonin synthesis capacity in autistic and nonautistic children. Ann Neurol 45 (1999), 287–295.
5. [5] Hagerman, R.J., Polussa, J., Treatment of the psychiatric problems associated with fragile X syndrome. Curr Opin Psychiatry 28 (2015), 107–112.
6. [6] Hanson, A.C., Hagerman, R.J., Serotonin dysregulation in fragile X syndrome: implications for treatment. Intractable Rare Dis Res 3 (2014), 110–117.
7. [7] Valdovinos, M.G., Parsa, R.A., Alexander, M.L., Results of a nation-wide survey evaluating psychotropic medication use in fragile X syndrome. J Dev Phys Disabil 21 (2009), 23–37.
8. [8] Indah Winarni, T., Chonchaiya, W., Adams, E., Au, J., Mu, Y., Rivera, S.M., et al. Sertraline may improve language developmental trajectory in young children with fragile X syndrome: a retrospective chart review. Autism Res Treat, 2012, 2012, 104317.
9. [9] Steingard, R.J., Zimnitzky, B., DeMaso, D.R., Bauman, M.L., Bucci, J.P., Sertraline treatment of transition-associated anxiety and agitation in children with autistic disorder. J Child Adolesc Psychopharmacol 7 (1997), 9–15.
10. [10] Schaefer, T.L., Davenport, M.H., Erickson, C.A., Emerging pharmacologic treatment options for fragile X syndrome. Appl Clin Genet 8 (2015), 75–93.
11. [11] Davenport, M.H., Schaefer, T.L., Friedmann, K.J., Fitzpatrick, S.E., Erickson, C.A., Pharmacotherapy for fragile X syndrome: progress to date. Drugs 76 (2016), 431–445.
12. [12] Costa, L., Spatuzza, M., D'Antoni, S., Bonaccorso, C.M., Trovato, C., Musumeci, S.A., et al. Activation of 5-HT7 serotonin receptors reverses metabotropic glutamate receptor-mediated synaptic plasticity in wild-type and FMR1 knockout mice, a model of fragile X syndrome. Biol Psychiatry 72 (2012), 924–933.
13. [13] Zhang, J., Hou, L., Klann, E., Nelson, D.L., Altered hippocampal synaptic plasticity in the FMR1 gene family knockout mouse models. J Neurophysiol 101 (2009), 2572–2580.
14. [14] Hagerman, R.J., Berry-Kravis, E., Kaufmann, W.E., Ono, M.Y., Tartaglia, N., Lachiewicz, A., et al. Advances in the treatment of fragile X syndrome. Pediatrics 123 (2009), 378–390.
15. [15] Wang, H., Pati, S., Pozzo-Miller, L., Doering, L.C., Targeted pharmacological treatment of autism spectrum disorders: fragile X and Rett syndromes. Front Cell Neurosci 9 (2015), 1–23.
16. [16] Berry-Kravis, E.M., Hessl, D., Rathmell, B., Zarevics, P., Cherubini, M., Walton-Bowen, K., et al. Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: a randomized, controlled, phase 2 trial. Sci Transl Med, 4, 2012 152ra127.
17. [17] Ligsay, A., Hagerman, R.J., Review of targeted treatments in fragile X syndrome. Intractable Rare Dis Res 5 (2016), 158–167.
18. [18] Greiss Hess, L., Fitzpatrick, S.E., Nguyen, D.V., Chen, Y., Gaul, K.N., Schneider, A., et al. A randomized double-blind, placebo-controlled trial of low-dose sertraline in young children with fragile X syndrome. J Dev Behav Pediatr 37 (2016), 619–628.
19. [19] Belmonte, M.K., Bourgeron, T., Fragile X syndrome and autism at the intersection of genetic and neural networks. Nat Neurosci 9 (2006), 1221–1225.
20. [20] Erickson, C.A., Ray, B., Maloney, B., Wink, L.K., Bowers, K., Schaefer, T.L., et al. Impact of acamprosate on plasma amyloid-b precursor protein in youth: a pilot analysis in fragile X syndrome-associated and idiopathic autism spectrum disorder suggests a pharmacodynamic protein marker. J Psychiatr Res 59 (2014), 220–228.
21. [21] Dziembowska, M., Pretto, D.I., Janusz, A., Kaczmarek, L., Leigh, M.J., Gabriel, N., et al. High MMP-9 activity levels in fragile X syndrome are lowered by minocycline. Am J Med Genet A 161A (2013), 1897–1903.
22. [22] Erickson, C.A., Wink, L.K., Ray, B., Early, M.C., Stiegelmeyer, E., Mathieu-Frasier, L., et al. Impact of acamprosate on behavior and brain-derived neurotrophic factor: an open-label study in youth with fragile X syndrome. Psychopharmacology 228 (2013), 75–84.
23. [23] Busner, J., Targum, S.D., The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry 4 (2007), 28–37.
24. [24] Tassone, F., Qi, L., Zhang, W., Hansen, R.L., Pessah, I.N., Hertz-Picciotto, I., MAOA, DBH and SLC6A4 variants in CHARGE: a case control study of autism spectrum disorders. Autism Res 4 (2011), 250–261.
25. [25] R. CoreTeam, R: a language and environment for statistical computing. 2016, R Foundation for Statistical Computing, Vienna.
26. [26] Leigh, M.J., Nguyen, D.V., Mu, Y., Winarni, T.I., Schneider, A., Chechi, T., et al. A randomized double-blind, placebo-controlled trial of minocycline in children and adolescents with fragile X syndrome. J Dev Behav Pediatr 34 (2013), 147–155.
27. [27] Taler, M., Miron, O., Gil-Ad, I., Weizman, A., Neuroprotective and procognitive effects of sertraline: in vitro and in vivo studies. Neurosci Lett 550 (2013), 93–97.
28. [28] Brody, G.H., Beach, S.R., Chen, Y.F., Obasi, E., Philibert, R.A., Kogan, S.M., et al. Perceived discrimination, serotonin transporter linked polymorphic region status, and the development of conduct problems. Dev Psychopathol 23 (2011), 617–627.
29. [29] Gatzeva-topalova, P.Z., Warner, L.R., Pardi, A., Carlos, M., 5HTTLPR genotype moderates the longitudinal impact of early caregiving on externalizing behavior. Dev Psychopathol 27 (2015), 7–18.
30. [30] Vaske, J., Newsome, J., Wright, J.P., Interaction of serotonin transporter linked polymorphic region and childhood neglect on criminal behavior and substance use for males and females. Dev Psychopathol 24 (2012), 181–193.
31. [31] Deckert, J., Catalano, M., Syagailo, Y.V., Bosi, M., Okladnova, O., Di Bella, D., et al. Excess of high activity monoamine oxidase A gene promoter alleles in female patients with panic disorder. Hum Mol Genet 8 (1999), 621–624.
32. [32] Binder, D.K., Scharfman, H.E., Brain-derived neurotrophic factor. Growth Factors 22:3 (2004), 123–131.
33. [33] Perlis, R.H., Pharmacogenetic studies of antidepressant response: how far from the clinic?. Psychiatr Clin North Am 30 (2007), 125–138.
34. [34] Kato, M., Serretti, A., Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol Psychiatry 15 (2010), 473–500.
35. [35] Gerretsen, P., Müller, D.J., Tiwari, A., Mamo, D., Pollock, B.G., The intersection of pharmacology, imaging, and genetics in the development of personalized medicine. Dialogues Clin Neurosci, 17, 2009 24–6, 47.
36. [36] Brett, Z.H., Sheridan, M., Humphreys, K., Smyke, A., Gleason, M.M., Fox, N., et al. A neurogenetics approach to defining differential susceptibility to institutional care. Int J Behav Dev 39 (2015), 150–160.
37. [37] Felmingham, K.L., Dobson-stone, C., Schofield, P.R., Quirk, G.J., Bryant, R.A., The brain-derived neurotrophic factor Val66Met polymorphism predicts response to exposure therapy in posttraumatic stress disorder. Biol Psychiatry 73 (2013), 1059–1063.
38. [38] Choi, M.-J., Kang, R.-H., Lim, S.-W., Oh, K.-S., Lee, M.-S., Brain-derived neurotrophic factor gene polymorphism (Val66Met) and citalopram response in major depressive disorder. Brain Res 1118 (2006), 176–182.
39. [39] Obach, R.S., Cox, L.M., Tremaine, L.M., Sertraline is matabolized by multiple cytrochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: an in vitro study. Drug Metab Dispos 33 (2005), 262–270.
40. [40] Cohen, I.L., Liu, X., Schutz, C., White, B.N., Jenkins, E.C., Brown, W.T., et al. Association of autism severity with a monoamine oxidase A functional polymorphism. Clin Genet 64 (2003), 190–197.
41. [41] Cohen, I.L., Liu, X., Lewis, M.E.S., Chudley, A., Forster-Gibson, C., Gonzalez, M., et al. Autism severity is associated with child and maternal MAOA genotypes. Clin Genet 79 (2011), 355–362.
42. [42] Davis, L.K., Hazlett, H.C., Librant, A.L., Nopoulos, P., Sheffield, V.C., Piven, J., et al. Cortical enlargement in autism is associated with a functional VNTR in the monoamine oxidase A gene. Am J Med Genet B Neuropsychiatr Genet 147B (2008), 1145–1151.
43. [43] Brune, C.W., Kim, S.-J., Salt, J., Leventhal, B.L., Lord, C., Cook, E.H. Jr., 5-HTTLPR genotype-specific phenotype in children and adolescents with autism. Am J Psychiatry 163 (2006), 2148–2156.
44. [44] Bilousova, T.V., Dansie, L., Ngo, M., Aye, J., Charles, J.R., Ethell, D.W., et al. Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile X mouse model. J Med Genet 46 (2009), 94–102.